Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants.

The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for KCS and features dormant and discontinued projects.

Key Targets of the KCS Pipeline Drugs Market

Some of the targets of the KCS pipeline drugs market are Calcineurin, Glucocorticoid Receptor, Actin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Cystic Fibrosis Transmembrane Conductance Regulator, Integrin Alpha L, Adiponectin Receptor Protein 1, and High Affinity Nerve Growth Factor Receptor among others.

KCS Pipeline Drugs Market, by Key Targets

KCS Pipeline Drugs Market, by Key Targets

For more insights on key targets, download a free report sample

Key Mechanisms of Action in the KCS Pipeline Drugs Market

The key mechanisms of action of the KCS pipeline drugs market are Calcineurin Inhibitor, Glucocorticoid Receptor Agonist, Actin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Adiponectin Receptor Protein 1 Agonist, High Affinity Nerve Growth Factor Receptor Agonist, and Integrin Alpha L Antagonist among others.

KCS Pipeline Drugs Market, by Key Mechanisms of Action

KCS Pipeline Drugs Market, by Key Mechanisms of Action

For more insights on key mechanisms of action, download a free report sample

Key Routes of Administration in the KCS Pipeline Drugs Market

The routes of administration in the KCS pipeline drugs market are ophthalmic, topical, oral, intravenous, transdermal, intraocular, nasal, and parenteral among others.

KCS Pipeline Drugs Market, by Routes of Administration

KCS Pipeline Drugs Market, by Routes of Administration

For more insights on routes of administration, download a free report sample

Key Molecule Types in the KCS Pipeline Drugs Market

The molecule types in the KCS pipeline drugs market are Small Molecule, Synthetic Peptide, Recombinant Protein, Biologic, Peptide, Synthetic Protein, and Antibody among others.

KCS Pipeline Drugs Market, by Molecule Types

KCS Pipeline Drugs Market, by Molecule Types

For more insights on molecule type, download a free report sample

Key Companies in the KCS Pipeline Drugs Market

Some of the key companies in the KCS pipeline drugs market are Azura Ophthalmics Pty Ltd, Aldeyra Therapeutics Inc, AxeroVision Inc, Intratus Inc, Novaliq GmbH, Ocular Therapeutix Inc, RegeneRx Biopharmaceuticals Inc, and AbbVie Inc among others.

KCS Pipeline Drugs Market, by Companies

KCS Pipeline Drugs Market, by Companies

For more insights on companies, download a free report sample

KCS Pipeline Drugs Market Report Overview

Key Targets Calcineurin, Glucocorticoid Receptor, Actin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Cystic Fibrosis Transmembrane Conductance Regulator, Integrin Alpha L, Adiponectin Receptor Protein 1, and High Affinity Nerve Growth Factor Receptor
Key Mechanisms of Action Calcineurin Inhibitor, Glucocorticoid Receptor Agonist, Actin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Adiponectin Receptor Protein 1 Agonist, High Affinity Nerve Growth Factor Receptor Agonist, and Integrin Alpha L Antagonist
Key Routes of Administration Ophthalmic, Topical, Oral, Intravenous, Transdermal, Intraocular, Nasal, and Parenteral
Key Molecule Types Small Molecule, Synthetic Peptide, Recombinant Protein, Biologic, Peptide, Synthetic Protein, and Antibody
Key Companies Azura Ophthalmics Pty Ltd, Aldeyra Therapeutics Inc, AxeroVision Inc, Intratus Inc, Novaliq GmbH, Ocular Therapeutix Inc, RegeneRx Biopharmaceuticals Inc, and AbbVie Inc

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AB2 Bio Ltd
AbbVie Inc
Abilita Bio Inc
Actinobac Biomed Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
Allosterix Ltd
Allysta Pharmaceuticals Inc
APIRx Pharmaceuticals USA LLC
Aramis Biosciences Inc
Ascendia Pharmaceuticals Inc
Aviara Pharmaceuticals Inc
Avixgen Inc
AxeroVision Inc
Azura Ophthalmics Pty Ltd
Bessor Pharma LLC
BRIM Biotechnology Inc
BSIM Therapeutics SA
Cambium Medical Technologies LLC
Cellix Bio Pvt Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cloudbreak Therapeutics LLC
Curexsys GmbH
Curigin Co Ltd
Daewoo Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
DHP Korea Co Ltd
Dompe Farmaceutici SpA
EncuraGen Co Ltd
Eye Bio Korea Co Ltd
FirstString Research Inc
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
H4Orphan Pharma
HanAll Biopharma Co Ltd
Huons Co Ltd
Huons Global Co Ltd
IACTA Pharmaceuticals Inc
Icure Pharmaceutical Inc
Ildong Pharmaceutical Co Ltd
Intratus Inc
Invitrx Therapeutics Inc
Ipsen SA
IVIEW Therapeutics Inc
Japan Tobacco Inc
Juvenescence UK Ltd
Kala Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratoires Thea SA
Link Biologics Ltd
LTT Bio-Pharma Co Ltd
Marinomed Biotech AG
MC2 Therapeutics AS
Medicon Pharmaceuticals Inc
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
Merck & Co Inc
Mimetogen Pharmaceuticals Inc
Mitotech SA
MyX Therapeutics Inc
Nanomerics Ltd
Neuroptika Inc
NicOx SA
Ningbo Xijian Pharmaceutical Technology Co Ltd
NovaCell Technology Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculis SA
Ocumension Therapeutics
OKYO Pharma Ltd
OncoNOx ApS
Ophrx Ltd
Oyster Point Pharma Inc
Palatin Technologies Inc
Panag Pharma Inc
PharmaResearch Co Ltd
Pinotbio Inc
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Protokinetix Inc
Qilu Pharmaceutical Co Ltd
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
Reven Holdings Inc
Rhizen Pharmaceuticals SA
RHNanopharmacuticals LLC
RiniSight Inc
Rudacure Co Ltd
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
SCAI Therapeutics
Seinda Pharmaceutical Guangzhou Corp
Senju Pharmaceutical Co Ltd
Serentrix LLC
Shenzhen Evergreen Therapeutics Co Ltd
SIFI SpA
Silk Technologies Ltd
Sinobioway Biomedical Co Ltd
Skye Bioscience Inc
Sol-Gel Technologies Ltd
Stuart Therapeutics Inc
Sun Pharmaceutical Industries Ltd
Surface Pharmaceuticals Inc
Surrozen Inc
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TagCyx Biotechnologies
Tarsius Pharma Ltd
TearSolutions Inc
Tetra Bio-Pharma Inc
Vanda Pharmaceuticals Inc
Viva Vision Biotech
Yuyu Pharma Inc
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Zhuhai Qiwei Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Keratoconjunctivitis Sicca (Dry Eye) – Overview

Keratoconjunctivitis Sicca (Dry Eye) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Keratoconjunctivitis Sicca (Dry Eye) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Keratoconjunctivitis Sicca (Dry Eye) – Companies Involved in Therapeutics Development

Keratoconjunctivitis Sicca (Dry Eye) – Drug Profiles

Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects

Keratoconjunctivitis Sicca (Dry Eye) – Discontinued Products

Keratoconjunctivitis Sicca (Dry Eye) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022

Keratoconjunctivitis Sicca (Dry Eye) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.